Journal Home > Volume 4 , Issue 1

Vascular factors to cognitive impairment in degenerative on non-degenerative diseases have been reported, examined, and debated for several decades. The various definitions of cognitive impairment due to vascular origins will make these results diverse. During this review, we are going to report currently update information of vascular contributions to cognitive function, in clinical or neuro-imaging findings. Risks factors and their managements also will be discussed and reported to have a comprehensive review.


menu
Abstract
Full text
Outline
About this article

Vascular contribution to cognition in stroke and Alzheimer’s disease

Show Author's information Yuanhan Yang1,2,3( )Jongling Fuh4,5Vincent C. T. Mok6
 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Taiwan, China
 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan, China
 Department of and Master’s Program in Neurology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung City 80708, Taiwan, China
 Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, China
 Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, China
 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

Abstract

Vascular factors to cognitive impairment in degenerative on non-degenerative diseases have been reported, examined, and debated for several decades. The various definitions of cognitive impairment due to vascular origins will make these results diverse. During this review, we are going to report currently update information of vascular contributions to cognitive function, in clinical or neuro-imaging findings. Risks factors and their managements also will be discussed and reported to have a comprehensive review.

Keywords:

Alzheimer’s disease, vascular cognitive impairment, post stroke dementia, white matter hyperintensity, diabetic mellitus, hypertension
Received: 01 March 2018 Revised: 15 April 2018 Accepted: 08 May 2018 Published: 25 November 2018 Issue date: September 2018
References(51)
[1]
Leshner AI, Landis S, Stroud C, Downey A. Preventing cognitive decline and dementia: A way forward. 2017.
[2]
Chen C, Homma A, Mok V, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N. Alzheimer’s disease with cerebrovascular disease: Current status in the Asia– Pacific region. Journal of Internal Medicine 2016, 280(4): 359-374.
[3]
Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003, 34(5): 1126-1129.
[4]
Iadecola C. The pathobiology of vascular dementia. Neuron 2013, 80(4): 844-866.
[5]
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, T O’Brien J, Barkhof F, Benavente OR. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet Neurology 2013, 12(8): 822-838.
[6]
Leys D, Hénon H, Mackowiak-Cordoliani M-A, Pasquier F. Poststroke dementia. The Lancet Neurology 2005, 4(11): 752-759.
[7]
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. The Lancet Neurology 2009, 8(11): 1006-1018.
[8]
Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, Wolf PA. Dementia after stroke: the Framingham Study. Stroke 2004, 35(6): 1264-1268.
[9]
Henon H, Pasquier F, Leys D. Poststroke dementia. Cerebrovascular diseases 2006, 22(1): 61-70.
[10]
Kokmen E, Whisnant J, O’fallon W, Chu C-P, Beard C. Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960–1984). Neurology 1996, 46(1): 154-159.
[11]
Rocca WA, Kokmen E. Frequency and distribution of vascular dementia. Alzheimer disease and associated disorders 1999, 13(S9–14.
[12]
Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E. Incidence of vascular dementia in Rochester, Minn, 1985–1989. Archives of neurology 2002, 59(10): 1605-1610.
[13]
Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Dalmonte E, Bianchin M, Mariani E. Incidence and etiology of dementia in a large elderly Italian population. Neurology 2005, 64(9): 1525- 1530.
[14]
Srikanth VK, Quinn SJ, Donnan GA, Saling MM, Thrift AG. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006, 37(10): 2479-2483.
[15]
Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, Chen S, Ho CL, Mok VC. Influence of amyloid-β on cognitive decline after stroke/transient ischemic attack: three-year longitudinal study. Stroke 2015, 46(11): 3074-3080.
[16]
Pohjasvaara T, Mäntylä R, Aronen HJ, Leskelä M, Salonen O, Kaste M, Erkinjuntti T. Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort. Journal of Neurology, Neurosurgery & Psychiatry 1999, 67(6): 742-748.
[17]
Cordoliani-Mackowiak M-A, Hénon H, Pruvo J-P, Pasquier F, Leys D. Poststroke dementia: Influence of hippocampal atrophy. Archives of neurology 2003, 60(4): 585-590.
[18]
Bastos-Leite AJ, van der Flier WM, van Straaten EC, Staekenborg SS, Scheltens P, Barkhof F. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke 2007, 38(12): 3182-3185.
[19]
Thiel A, Cechetto DF, Heiss W-D, Hachinski V, Whitehead SN. Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke 2014, 45(9): 2825-2829.
[20]
Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Archives of neurology 2012, 69(12): 1621-1627.
[21]
Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D, Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Archives of neurology 2008, 65(9): 1202-1208.
[22]
Swardfager W, Yu D, Ramirez J, Cogo-Moreira H, Szilagyi G, Holmes MF, Scott CJ, Scola G, Chan PC, Chen J. Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer’s disease: A preliminary report. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2017, 7(56–60).
[23]
Choi JC. Genetics of cerebral small vessel disease. Journal of stroke 2015, 17(1): 7.
[24]
Paternoster L, Chen W, Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19 000 subjects. Stroke 2009, 40(6): 2020-2026.
[25]
Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1)(dipeptidyl carboxypeptidase 1). Nucleic acids research 1992, 20(6): 1433.
[26]
Yang YH, Lai CL, Tyan YC, Chou MC, Wang LC, Yang MH, Liu CK. Angiotensin-converting enzyme gene and plasma protein level in Alzheimer’s disease in Taiwanese. Age and Ageing 2011, 40(2): 238-242.
[27]
Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. Journal of Biological Chemistry 2005, 280(45): 37644-37650.
[28]
He Q, Fan C, Yu M, Wallar G, Zhang Z-F, Wang L, Zhang X, Hu R. Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population. PLoS One 2013, 8(10): e75870.
[29]
Chou PS, Wu MN, Chou MC, Chien I, Yang YH. Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer’s disease. Geriatrics & Gerontology International 2017, 17(10): 1544-1550.
[30]
Goldstein LB. A Primer on Stroke Prevention and TREATment: An Overview Based on AHA/ASA Guidelines. John Wiley & Sons, 2011.
[31]
Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology 2011, 10(9): 819-828.
[32]
Yang Y-H, Roe CM, Morris JC. Relationship between late-life hypertension, blood pressure, and Alzheimer’s disease. American Journal of Alzheimer’s Disease & Other Dementias 2011, 26(6): 457-462.
[33]
Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. The Lancet Neurology 2008, 7(8): 683-689.
[34]
Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene M-R, Babeanu S, Bossini A, Gil-Extremera B, Girerd X. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. The Lancet 1998, 352(9137): 1347-1351.
[35]
Forette F, Seux M-L, Staessen JA, Thijs L, Babarskiene M-R, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of Internal Medicine 2002, 162(18): 2046- 2052.
[36]
Collaborative P, Neal B, MacMahon S. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163: 1069-1075.
[37]
Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser M-G, Guillon P, Macmahon S, Mazoyer B, Neal B, Woodward M. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation 2005, 112(11): 1644-1650.
[38]
Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Archives of Neurology 2012, 69(12): 1632-1638.
[39]
Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I. Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer’s Disease. Journal of the American Geriatrics Society 2015, 63(9): 1749-1756.
[40]
Tai S-Y, Chen C-H, Chien C-Y, Yang Y-H, Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study. BMC Neurology 2017, 17(1): 40.
[41]
Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: Phosphodiesterase inhibitors. British Journal of Clinical Pharmacology 2011, 72(4): 634-646.
[42]
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. The Lancet Neurology 2010, 9(10): 959-968.
[43]
Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012, 43(2): 499-506.
[44]
Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989, 20(5): 668-673.
[45]
Park SH, Kim JH, Bae SS, Hong KW, Lee D-S, Leem JY, Choi BT, Shin HK. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochemical and Biophysical Research Communications 2011, 408(4): 602-608.
[46]
Tai S-Y, Chien C-Y, Chang Y-H, Yang Y-H. Cilostazol use is associated with reduced risk of dementia: A nationwide cohort study. Neurotherapeutics 2017, 14(3): 784-791.
[47]
Cheng P-Y, Sy H-N, Wu S-L, Wang W-F, Chen Y-Y, Newly diagnosed type 2 diabetes and risk of dementia: A population-based 7-year follow-up study in Taiwan. Journal of Diabetes and its Complications 2012, 26(5): 382-387.
[48]
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. The Lancet Neurology 2006, 5(1): 64-74.
[49]
Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation. Journal of Biological Chemistry 2005, 280(22): 21453-21462.
[50]
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. Journal of Neuroscience 2000, 20(2): 558- 567.
[51]
Chou P-S, Ho B-L, Yang Y-H. Effects of pioglitazone on the incidence of dementia in patients with diabetes. Journal of Diabetes and its Complications 2017, 31(6): 1053-1057.
Publication history
Copyright
Rights and permissions

Publication history

Received: 01 March 2018
Revised: 15 April 2018
Accepted: 08 May 2018
Published: 25 November 2018
Issue date: September 2018

Copyright

© The authors 2018

Rights and permissions

This article is published with open access at journals.sagepub.com/home/BSA

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/ en-us/nam/open-access-at-sage).

Return